Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00970203 |
Recruitment Status :
Completed
First Posted : September 2, 2009
Results First Posted : May 7, 2020
Last Update Posted : November 3, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cancer of Prostate Cancer of the Prostate Neoplasms, Prostate Neoplasms, Prostatic Prostate Cancer Prostate Neoplasms Prostatic Cancer | Biological: androgen ablation (AA) Biological: DC1 vaccine | Phase 2 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 13 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Feasibility, Safety and Efficacy Evaluation of Alpha-Type 1 Dendritic Cell(DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With PSA Progression After Local Therapy for Prostate Cancer |
Study Start Date : | September 2009 |
Actual Primary Completion Date : | October 5, 2018 |
Actual Study Completion Date : | October 5, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Cohort A
3 months of androgen ablation followed at PSA progression by 3 months of the combination of androgen ablation + DC1 vaccine AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells |
Biological: androgen ablation (AA)
Lupron 22.5 mg or Zoladex 10.8 mg Biological: DC1 vaccine 3-5 x 10e6 cells total
Other Name: alpha dendritic cell 1 vaccine |
Experimental: Cohort B
3 months of the combination of androgen ablation + DC1 vaccine followed at PSA progression by 3 months of androgen ablation AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells |
Biological: androgen ablation (AA)
Lupron 22.5 mg or Zoladex 10.8 mg Biological: DC1 vaccine 3-5 x 10e6 cells total
Other Name: alpha dendritic cell 1 vaccine |
- Percentage of Patients to Successfully Generate and Administer the Alpha-DC1 Vaccine [ Time Frame: 16 weeks ]The percentage of patients for which the alpha-DC1 vaccine was generated and for which 4 vaccine injections were administered (1 injection every 4 weeks).
- Tolerability and Toxicity of the Alpha-DC1 Vaccine [ Time Frame: 16 weeks ]The percentage of patients who experienced vaccine related toxicity.
- The Effect of the DC1 Vaccine on Time to PSA Progression Compared to AA Alone [ Time Frame: Approximately 18 months ]The mean difference between time to relapse on androgen ablation plus alpha DC-1 vaccine vs androgen ablation
- Change in PSA Velocity Prior to and Following the Proposed Treatment. [ Time Frame: Approximately 18 months ]
- Evaluate (in All Subjects) the Vaccination-induced DTH Responses to LNCap, the Cell Line Vaccine, and to Compare This With Vaccination-induced Responses to Tumor-untreated Antigen (KLH) [ Time Frame: Approximately 17 weeks ]
- Evaluate the Vaccination-induced Changes of Th1/Th2 Profiles of the Responses to PAP and PSMA [ Time Frame: Approximately 18 to 24 months ]
- Evaluate the CTL Responses in Blood to the Whole LNCap Cells (in All Subjects) and (in All Subjects Who Are HLA-A2 Positive) the CTL Responses to HLA-A2.1 Restricted Peptides Derived From PAP and PSMA [ Time Frame: Approximately 18 to 24 months ]
- Comprehensively Evaluate the CD4+ and CD8+ T Cell Responses (Fine Specificity and Th1/Th2/Treg Cytokine Profile) to the Previously-identified and Novel Immunogenic Epitopes of PAP and PSMA, Using the EPIMAX System [ Time Frame: Approximately 18 to 24 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Eligibility Criteria
- Patients with histologically proven prostate cancer and tumors limited to the prostate (including seminal vesicle involvement, provided all visible disease was surgically removed) who have completed local therapy and have an elevated PSA after surgery or rising PSA after radiation therapy, as defined below.
- Age 18 years or older
- Histologically confirmed diagnosis of prostate cancer.
- Previous treatment with definitive surgery or radiation therapy or both.
- No evidence of metastatic disease on physical exam, CT/MRI/CXR (see Section 7.1 for radiologic imaging), and bone scan within 4 weeks prior to randomization.
- Prior neoadjuvant/adjuvant hormonal, androgen deprivation therapy, or chemotherapy is allowed if it was last used > 12 months prior to first vaccination.
- No therapy modulating testosterone levels (such as leuteinizing-hormone releasing-hormone agonists/antagonists and antiandrogens) is permitted within 12 months prior to first vaccination. Agents such as 5α-reductase inhibitors, ketoconazole, megestrol acetate, systemic steroids (replacement doses of steroids are allowed), PC-SPES, and Saw Palmetto are not permitted at any time during the period that the PSA values are being collected.
- Hormone-sensitive prostate cancer as evident by a serum total testosterone level > 150 ng/dL or > 6 nmol/L at the time of enrollment within 4 weeks prior to randomization.
- All patients must have evidence of biochemical progression as determined by a reference PSA value followed by 1 confirmatory rising PSA value, higher than the previous value, obtained at least 2 weeks apart. All of these PSA values must be obtained at the same reference lab, and all must be done within 6 months prior to enrollment.
- The most recent of the PSA values must be ≥ 2.0 ng/mL. This measurement must be obtained within 1 month prior to enrollment.
- The PSA doubling time (PSA-DT) must be less than 12 months.
- ECOG performance status 0 or 1.
-
Patients must have normal organ and marrow function as defined below:
- Absolute neutrophil count > 1,500/µL
- Platelets > 100,000/µL
- Total bilirubin 1.5 x upper limit of normal (ULN)
- SGOT (AST) and SGPT (ALT) < 2.5 x institutional ULN
- Creatinine 1.5 x ULN
- The effects of dendritic cell vaccines on the developing human fetus are unknown. For this reason men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation.
Exclusion Criteria
- Patients must not be receiving other investigational agents or concurrent anticancer therapy.
- No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Patients must not have active eczema, atopic dermatitis, or other exfoliative skin conditions (e.g., burns, impetigo, varicella zoster, severe acne, contact dermatitis, psoriasis, herpes or other open rashes or wounds).
- Presence of an active acute or chronic infection, including urinary tract infection, HIV or viral hepatitis. HIV patients are excluded based on immunosuppression which may render them unable to respond to the vaccine; patients with chronic hepatitis are excluded because of concern that hepatitis could be exacerbated by the injections. If clinically indicate, HIV/viral hepatitis testing will be performed to confirm status.
- Patients with a history of auto-immune disease such as, but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis. Patients receiving replacement thyroid hormone would be eligible.
- No concurrent use of systemic steroids, except for local (topical, nasal, or inhaled) steroid use. Adrenal replacement doses of corticosteroids are allowed.
- Subjects with concurrent additional malignancy (with exception of non-melanoma skin cancers and superficial bladder cancer or malignancy within last 3 years).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00970203
United States, Pennsylvania | |
University of Pittsburgh Cancer institute | |
Pittsburgh, Pennsylvania, United States, 15232 |
Principal Investigator: | Leonard J Appleman, MD, PhD | University of Pittsburgh |
Documents provided by Roswell Park Cancer Institute:
Responsible Party: | Roswell Park Cancer Institute |
ClinicalTrials.gov Identifier: | NCT00970203 |
Other Study ID Numbers: |
06-070 |
First Posted: | September 2, 2009 Key Record Dates |
Results First Posted: | May 7, 2020 |
Last Update Posted: | November 3, 2020 |
Last Verified: | October 2020 |
Vaccine Androgen Ablation PSA Progression |
Prostatic Neoplasms Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Prostatic Diseases |
Vaccines Androgens Immunologic Factors Physiological Effects of Drugs Hormones Hormones, Hormone Substitutes, and Hormone Antagonists |